中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2012年
3期
266-269
,共4页
庄喜兵%陈伟%乔田奎%查琳%袁素娟
莊喜兵%陳偉%喬田奎%查琳%袁素娟
장희병%진위%교전규%사림%원소연
Lewis肺癌%含非甲基化二核苷酸的寡脱氧核苷酸%X射线照射%肿瘤生长延迟%凋亡
Lewis肺癌%含非甲基化二覈苷痠的寡脫氧覈苷痠%X射線照射%腫瘤生長延遲%凋亡
Lewis폐암%함비갑기화이핵감산적과탈양핵감산%X사선조사%종류생장연지%조망
Lewis lung cancer%Unmethylated cytosine-phosphate-guanine oligodeoxynucleotide,CpG ODN%X-ray irradiation%Tumor growth delay%Apoptosis
目的 探讨含非甲基化二核苷酸的寡脱氧核苷酸( unmethylated cytosine-phosphate-guanine oligodeoxynucleotide,CpG ODN) 1826对X射线照射荷瘤小鼠Lewis肺癌的联合作用及其剂量-效应关系.方法 在C57BL/6J纯系小鼠右前腋窝接种Lewis肺癌细胞,制备荷瘤小鼠模型.将64只荷瘤小鼠按完全随机化方法随机分为对照组、X射线照射(IR)组、低剂量CpG ODN1826组(0.15 mg)、中剂量CpG ODN1826组(0.30 rag)、高剂量CpG ODN1826组(0.45 mg)、低剂量CpG ODN826+ IR组(CPG1826 0.15 mg+ IR)、中剂量CpG ODN1826+ IR组(CpG 0.30 mg+ IR)和高剂量CpG ODN1826+ IR组(CpG 0.45 mg+ IR),每组8只.实验的第1、2、9天注射CpG ODN1826.实验的第2天开始X射线照射,1次/d,2.50 Gy/次,总剂量12.50 Gy.观察各组移植瘤生长速度和各治疗组肿瘤生长延迟时间(TGD),用DNA断裂的原位末端标记法检测细胞凋亡.结果 成功建立荷瘤小鼠Lewis肺癌模型,成瘤率为100％.经治疗后,各组小鼠肿瘤体积都较对照组明显减小,CpG ODN1826 0.45 mg+ IR组移植瘤体积最小.DNA断裂的原位末端标记法(TUNEL)法检测细胞凋亡率分别为(2.40±0.55)％、(5.50±0.76)％、(7.13±0.83)％、(11.63±1.06)％、(19.13±0.83)％、(12.88±0.83)％、(20.57±2.37)％和(28.17±3.31)％.各治疗组都明显高于对照组(t=11.15、7.91、17.82、39.48、24.73、16.61和17.05,P＜0.05),不同剂量CpG ODN1826 +IR组显著高于IR组(t=13.78、15.08和17.47,P ＜0.05)和不同剂量CpG ODN1826组(t=18.53、9.66和7.51,P ＜0.05).结论 CpG ODN1826能明显地抑制肿瘤细胞生长,促进肿瘤细胞凋亡,且呈剂量-效应关系.
目的 探討含非甲基化二覈苷痠的寡脫氧覈苷痠( unmethylated cytosine-phosphate-guanine oligodeoxynucleotide,CpG ODN) 1826對X射線照射荷瘤小鼠Lewis肺癌的聯閤作用及其劑量-效應關繫.方法 在C57BL/6J純繫小鼠右前腋窩接種Lewis肺癌細胞,製備荷瘤小鼠模型.將64隻荷瘤小鼠按完全隨機化方法隨機分為對照組、X射線照射(IR)組、低劑量CpG ODN1826組(0.15 mg)、中劑量CpG ODN1826組(0.30 rag)、高劑量CpG ODN1826組(0.45 mg)、低劑量CpG ODN826+ IR組(CPG1826 0.15 mg+ IR)、中劑量CpG ODN1826+ IR組(CpG 0.30 mg+ IR)和高劑量CpG ODN1826+ IR組(CpG 0.45 mg+ IR),每組8隻.實驗的第1、2、9天註射CpG ODN1826.實驗的第2天開始X射線照射,1次/d,2.50 Gy/次,總劑量12.50 Gy.觀察各組移植瘤生長速度和各治療組腫瘤生長延遲時間(TGD),用DNA斷裂的原位末耑標記法檢測細胞凋亡.結果 成功建立荷瘤小鼠Lewis肺癌模型,成瘤率為100％.經治療後,各組小鼠腫瘤體積都較對照組明顯減小,CpG ODN1826 0.45 mg+ IR組移植瘤體積最小.DNA斷裂的原位末耑標記法(TUNEL)法檢測細胞凋亡率分彆為(2.40±0.55)％、(5.50±0.76)％、(7.13±0.83)％、(11.63±1.06)％、(19.13±0.83)％、(12.88±0.83)％、(20.57±2.37)％和(28.17±3.31)％.各治療組都明顯高于對照組(t=11.15、7.91、17.82、39.48、24.73、16.61和17.05,P＜0.05),不同劑量CpG ODN1826 +IR組顯著高于IR組(t=13.78、15.08和17.47,P ＜0.05)和不同劑量CpG ODN1826組(t=18.53、9.66和7.51,P ＜0.05).結論 CpG ODN1826能明顯地抑製腫瘤細胞生長,促進腫瘤細胞凋亡,且呈劑量-效應關繫.
목적 탐토함비갑기화이핵감산적과탈양핵감산( unmethylated cytosine-phosphate-guanine oligodeoxynucleotide,CpG ODN) 1826대X사선조사하류소서Lewis폐암적연합작용급기제량-효응관계.방법 재C57BL/6J순계소서우전액와접충Lewis폐암세포,제비하류소서모형.장64지하류소서안완전수궤화방법수궤분위대조조、X사선조사(IR)조、저제량CpG ODN1826조(0.15 mg)、중제량CpG ODN1826조(0.30 rag)、고제량CpG ODN1826조(0.45 mg)、저제량CpG ODN826+ IR조(CPG1826 0.15 mg+ IR)、중제량CpG ODN1826+ IR조(CpG 0.30 mg+ IR)화고제량CpG ODN1826+ IR조(CpG 0.45 mg+ IR),매조8지.실험적제1、2、9천주사CpG ODN1826.실험적제2천개시X사선조사,1차/d,2.50 Gy/차,총제량12.50 Gy.관찰각조이식류생장속도화각치료조종류생장연지시간(TGD),용DNA단렬적원위말단표기법검측세포조망.결과 성공건립하류소서Lewis폐암모형,성류솔위100％.경치료후,각조소서종류체적도교대조조명현감소,CpG ODN1826 0.45 mg+ IR조이식류체적최소.DNA단렬적원위말단표기법(TUNEL)법검측세포조망솔분별위(2.40±0.55)％、(5.50±0.76)％、(7.13±0.83)％、(11.63±1.06)％、(19.13±0.83)％、(12.88±0.83)％、(20.57±2.37)％화(28.17±3.31)％.각치료조도명현고우대조조(t=11.15、7.91、17.82、39.48、24.73、16.61화17.05,P＜0.05),불동제량CpG ODN1826 +IR조현저고우IR조(t=13.78、15.08화17.47,P ＜0.05)화불동제량CpG ODN1826조(t=18.53、9.66화7.51,P ＜0.05).결론 CpG ODN1826능명현지억제종류세포생장,촉진종류세포조망,차정제량-효응관계.
Objective To explore the combination effect of unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) 1826 and X-rays on Lewis lung cancer in mouse and the dose response of CpG ODN.Methods The tumor-bearing mouse model was established by injecting Lewis lung cancer cells into the right infra-axillary dermis of mouse.Sixty-four C57BL /6 J mice were evenly randomized into eight groups with 8 mice each:control group,IR group,CpG OND1826 0.15 mg group,CpG OND1826 0.3 mg group,CpG OND1826 0.45 mg group,CpG OND1826 0.15 mg + IR group,CpG OND1826 0.30 mg+ IR group,and CpG OND1826 0.45 mg + IR group.On the 1st,2nd,and 9th days,CpG ODN was injected into mouse.After 3 hours of injection,the mice were start to irradiate with X-rays once a day on the 2nd-6th days,and the total dose was 12.50 Gy.Tumor growth and TGD were measured,and the apoptosis of tumor cells were examined with TUNEL.Results The Lewis lung cancer-bearing model was successfully established in all mice.Under the treatments of CpG OND1826 and irradiation,the tumor volumes were smaller than that of control group,and the tumor volumes of CpG OND1826 0.45 mg+IR group was the smallest.TUNEL results revealed that the apoptosis rate were (2.40 ± 0.51 )％ in control group,(5.62 ±0.50)％ in IR,(7.13±0.83)％ in CpG OND1826 0.15 mg,(11.63±1.06)％ in CpG OND1826 0.3 mg,(19.13 ±0.83)％ in CpG OND1826 0.45 rag,( 12.88±0.83)％ in CpG OND1826 0.15 mg+ IR,(20.57±2.37)％ in CpG OND1826 0.3 mg+ IR,and (28.17 ±3.31)％ in CpG OND1826 0.45 mg + IR group,and thus the apoptosis rate of every therapy group was higher than that in control ( t=11.15,7.91,17.82,39.48,24.73,16.61 and 17.05,P＜0.05).The apoptosis rates of CpG ODN1826 plus X-ray irradiation group were significantly higher than those in IR alone ( t =13.78,15.08 and 17.47,P＜0.05 ) or CpG ODN group (t=18.53,9.66and7.51,P＜0.05).Conclusions CpG ODN1826 can dramatically increase the efficiency of radiotherapy by inhibiting tumor growth and promoting lumor apoptosis.
